The CLEOPATRA trial set the stage for establishing pertuzumab, an anti-HER2 dimerization inhibitor [13], in combination with trastuzumab plus chemotherapy as the standard for care in the adjuvant setting for HER2-positive BC; the regiment demonstrated a 6.1 month increase in overall survival (OS) [14]. Here, ERBB2 is linked to breast cancer.